Current treatments of lupus nephritis;Traitements actuels des néphropathies lupiques

Revue du Rhumatisme (Edition Francaise)

Volumn 74, Issue 8, 2007, Pages 759-764

  Fakhouri, Fadi ^a   Lesavre, Philippe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Azathioprine; Glomerulonephritis; Immunosuppressive therapy; Mycophenolate mofetil; Prednisone; Rituximab; Systemic lupus erythematosus

Indexed keywords

EID: 34548543143     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2007.07.004     Document Type: Short Survey

References (38)

1. Bujan S., Ordi-Ros J., Paredes J., Mauri M., Matas L., Cortes J., et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann. Rheum. Dis. 62 (2003) 859-865
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 82 (2003) 299-308
3. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15 (2004) 241-250
4. Elliot V., Cairns T., and Cook H.T. Evolution of lesions over 10 years in a patient with SLE : flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis. Am. J. Kidney Dis. 47 (2006) 184-190
5. American College of Rheumatology ad hoc committee on systemic lupus erythematous response criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 50 (2004) 3418-3426
6. American College of Rheumatology ad hoc committee on systemic lupus erythematous response criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 54 (2006) 421-432
7. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., and Rohde R.D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am. J. Kidney Dis. 35 (2000) 904-914
8. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon Garrido E., Danieli M.G., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50 (2004) 3934-3940
9. Flanc R.S., Roberts M.A., Strippoli G.F., Chadban S.J., Kerr P.G., and Atkins R.C. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. 43 (2004) 197-208
10. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., Garrido Ed Ede R., Danieli M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46 (2002) 2121-2131
11. Houssiau F.A. Management of lupus nephritis: an update. J. Am. Soc. Nephrol. 15 (2004) 2694-2704
12. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343 (2000) 1156-1162
13. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (2005) 2219-2228
14. Grootscholten C., Ligtenberg G., Hagen E.C., van den Wall Bake A.W., de Glas-Vos J.W., Bijl M., et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70 (2006) 732-742
15. Mok C.C., Ying K.Y., Tang S., Leung C.Y., Lee K.W., Ng W.L., et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 50 (2004) 2559-2568
16. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350 (2004) 971-980
17. Grootscholten C., and Berden J.H. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol. Dial. Transplant. 21 (2006) 1465-1469
18. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 2673-2677
19. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
20. Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 148 (2006) 623-627
21. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54 (2006) 2970-2982
22. Gunnarsson I., Sundelin B., Jonsdottir T., Jacobson S.H., Henriksson E.W., and van Vollenhoven R.F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56 (2007) 1263-1272
23. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66 (2007) 470-475
24. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 455-459
25. Hu W., Liu Z., Shen S., Li S., Yao X., Chen H., et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. (Engl.) 116 (2003) 1827-1830
26. Mok C.C., Ying K.Y., Lau C.S., Yim C.W., Ng W.L., Wong W.S., et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am. J. Kidney Dis. 43 (2004) 269-276
27. Austin H., and Balow J. Long-term observations in a prospective clinical trial of Prednisone, Cyclosporine and Cyclophosphamide in lupus membranous nephropathy. J. Am. Soc. Nephrol. 15 (2004) 54A
28. Spetie D.N., Tang Y., Rovin B.H., Nadasdy T., Nadasdy G., Pesavento T.E., et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 66 (2004) 2411-2415
29. Borba E.F., Guedes L.K., Christmann R.B., Figueiredo C.P., Goncalves C.R., and Bonfa E. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol. Int. 26 (2006) 1078-1083
30. Teplitsky V., Shoenfeld Y., and Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 15 (2006) 319-325
31. Riboldi P., Gerosa M., and Meroni P.L. Statins and autoimmune diseases. Lupus 14 (2005) 765-768
32. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract. Res. Clin. Rheumatol. 19 (2005) 823-838
33. de Nijs R.N., Jacobs J.W., Lems W.F., Laan R.F., Algra A., Huisman A.M., et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 355 (2006) 675-684
34. Somers E.C., Marder W., Christman G.M., Ognenovski V., and McCune W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 52 (2005) 2761-2767
35. Brouwer J.L., Bijl M., Veeger N.J., Kluin-Nelemans H.C., and van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104 (2004) 143-148
36. Karlson E.W., Liang M.H., Eaton H., Huang J., Fitzgerald L., Rogers M.P., et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 1832-1841
37. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349 (2003) 1526-1533
38. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 (2003) 2407-2415